Block & Leviton LLP Reminds Shareholders of Important Deadlines: CTL, INGN, ZVO, ARA
BOSTON, May 03, 2019 (GLOBE NEWSWIRE) -- Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, reminds investors of the important deadlines listed below. If you have purchased or otherwise acquired any of the securities listed below, please contact Block & Leviton LLP at (888) 868-2385, by email at info@blockesq.com, or by visiting http://shareholder.law/.
CenturyLink, Inc. (NYSE: CTL)
Lead Plaintiff Deadline: May 6, 2019
Class Period: May 10, 2018 to March 4, 2019
Learn more about this class action at: http://shareholder.law/centurylink
Inogen, Inc. (NASDAQ: INGN)
Lead Plaintiff Deadline: May 6, 2019
Class Period: November 8, 2017 to February 26, 2019
Learn more about this class action at: http://shareholder.law/inogen
Bridgepoint Education Inc. (NASDAQ: ZVO)
Lead Plaintiff Deadline: May 10, 2019
Class Period: March 8, 2016 to March 7, 2019
Learn more about this class action at: http://shareholder.law/bridgepoint
American Renal Associates Holdings, Inc. (NYSE: ARA)
Lead Plaintiff Deadline: May 28, 2019
Class Period: August 10, 2016 to March 27, 2019
Learn more about this class action at: http://shareholder.law/ara
Block & Leviton LLP was recently ranked 4th among securities litigation firms by ISS for recoveries in 2017. The firm represents many of the nation's largest institutional investors and numerous individual investors in securities litigation throughout the country. Indeed, its lawyers have recovered billions of dollars for its clients.
This notice may constitute attorney advertising.
CONTACT:
BLOCK & LEVITON LLP
260 Franklin Street, Suite 1860
Boston, MA 02110
(617) 398-5660 phone
info@blockesq.com
SOURCE Block & Leviton LLP
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
